在先进的结直肠癌中进行EORTC临床试验的欧洲查平台"SPECTAcolor"
G Folprecht1, M Morfouace2,3, M Collienne3,4
1University Hospital Carl Gustav Carus, University Cancer Center, Dresden, Germany.
ESMO gastrointestinal oncology
|February 6, 2026
概括
针对结直肠癌患者有效临床试验准入的查平台 (SPECTAcolor) 成功查了1000多名患者的结直肠癌分子标志物. 这个学术平台证明了中央测试的可行性,并为未来的研究产生了有价值的数据集.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断
- 临床试验 临床试验
背景情况:
- 欧洲癌症研究和治疗组织 (EORTC) 建立了为色直肠患者提供高效临床试验访问的查平台 (SPECTAcolor).
- SPECTAcolor旨在为结直肠癌 (CRC) 患者提供集中分子测试,以促进他们参加向治疗试验.
研究的目的:
- 评估一个学术查平台的可行性,用于在晚期结直肠癌中进行分子测试.
- 为了未来的研究,为800多名CRC患者生成一个全面的分子和临床数据集.
主要方法:
- 从2013年9月到2015年底,在11个欧洲国家招募了晚期或转移性结直肠癌患者.
- 对关键基因 (KRAS,NRAS,BRAF,PI3K) 和微卫星不稳定性高 (MSI-H) 状态的患者样本进行集中分子测试,随后进行下一代测序 (300基因组) 和RNA分析.
- 对所有被招募的患者进行临床结果数据收集和随访.
主要成果:
- 招募了1000多名患者,可获得845名转移性CRC患者的分子和临床数据.
- 在KRAS,NRAS和BRAF的本地和中央测试之间观察到很高的一致性 (κ=0.82-0.95),对MSI-H的中等一致性 (κ=0.55).
- 平均整体存活时间为56.6个月;BRCA,FGFR和HER2的变化显示了较短存活的趋势.
结论:
- SPECTAcolor证明了招募到一个学术查平台的可行性,用于结直肠癌中的分子测试.
- 集中的,质量保证的分子测试是有价值的,即使对于通常评估的标记物.
- 生成的数据集和相关样本为未来的生物标志物验证和学术研究提供了重要的资源,尽管将平台与试验联系起来并确保可持续性仍然是挑战.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...


